Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.67.

A number of equities analysts have issued reports on VRCA shares. Lake Street Capital began coverage on Verrica Pharmaceuticals in a report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective for the company. Wall Street Zen upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th.

Verrica Pharmaceuticals Trading Up 1.0%

VRCA opened at $4.18 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. Verrica Pharmaceuticals has a 52 week low of $3.28 and a 52 week high of $9.82. The stock has a market cap of $71.81 million, a PE ratio of -2.50 and a beta of 1.60. The business has a 50 day moving average of $4.88 and a 200-day moving average of $5.60.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Renaissance Technologies LLC grew its stake in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 22.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,360 shares of the company’s stock after acquiring an additional 5,960 shares during the quarter. Renaissance Technologies LLC owned about 0.19% of Verrica Pharmaceuticals worth $171,000 as of its most recent SEC filing. 42.45% of the stock is currently owned by institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases with limited or inadequate therapeutic options. The company’s work centers on topical therapies designed for use in dermatology practices and other healthcare settings.

Verrica’s lead product, YCANTHE (cantharidin), is a topical solution approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children two years of age and older.